The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 33166276.
- Also identified by DOI 10.1371/journal.pcbi.1008332 and PMC identifier 7676656.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The tumor mutational burden (TMB) is increasingly recognized as an emerging biomarker that predicts improved outcomes or response to immune checkpoint inhibitors in cancer. A multitude of technical and biological factors make it difficult to compare TMB values across platforms, histologies, and treatments. Here, we present a mechanistic model that explains the association between panel size, histology, and TMB threshold with panel performance and survival outcome and demonstrate the limitations of existing methods utilized to harmonize TMB across platforms.
Medical subject headings
- Biomarkers, Tumor
- Immunotherapy
- Mutation
- Neoplasms
- Patient Selection